Navigation Links
Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
Date:6/9/2011

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

The total award is for $3,698,130, with the Florida campus of Scripps Research receiving $2.19 million over five years and the University of Kansas receiving approximately $1.5 million.

According to the National Survey on Drug Use and Health, in 2009 an estimated 21.8 million Americans aged 12 or older had used illicit drugs within the last month, approximately 8.7 percent of the population aged 12 or older, an increase over 2008. Illicit drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, and prescription-type psychotherapeutics used nonmedically. Multiple drug use is common among substance abusers, according to the National Institute on Drug Abuse (NIDA).

The grant funds research directed by Scripps Research Associate Professor Laura Bohn to develop new compounds targeting a specific receptor playing a critical role in the persistence of compulsive drug seeking and taking. (Receptors bind substances, triggering certain biological effects.)

"All addictive drugs share certain reinforcing properties that make it difficult to quit and remain abstinent," said Bohn. "There is significant evidence spanning decades that the kappa opioid receptor is a good candidate in terms of disrupting this addictive cycle. Right now we're in the early stages of R&D but we have a lot of confidence in what we've studied so far."

The kappa opioid receptor, which is located on neurons, helps regulate the release of dopamine a neurotransmitter that plays a key role in drug addiction. Drugs of abuse often cause the brain to release large amounts of dopamine, flooding the brain's reward system and reinforcing the addictive cycle.

The basis of the studies proposed in the current award results from years of screening by the Molecular Libraries Probe Production Centers Network supported by the NIH. After screening more than 300,000 small molecule compounds, the group, along with the specialized chemistry center at the University of Kansas, identified five novel chemical candidates for clinical development.

For the next five years, the collaborative research team at Scripps Research and the University of Kansas will work to improve selectivity, potency, efficacy, and bioavailability of these compounds to provide a strong preclinical framework for clinical utilization of new drugs targeting the kappa opioid receptor in the hopes of finding a way to help improve recovery from a variety of addictive drugs.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research scientist wins $1.9 million grant to study malaria
2. Scripps Research scientists find way to block stress-related cell death
3. Scripps Research scientists find key mechanism in transition to alcohol dependence
4. Scripps Research scientists create new genetic model of premature aging diseases
5. Scripps Research scientists identify mechanism of long-term memory
6. Scripps Research scientists uncover new DNA role in modifying gene function
7. Scripps Research scientists find dual switch regulates fat formation
8. Common chaperone protein found to work in surprising way, say Scripps Research scientists
9. Dr. Daniel Von Hoff presented with top genomics award from Scripps
10. Scripps Research team discovers new details about medically important protein family
11. Scripps Research scientists develop new test for pluripotent stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology: